Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update


Demirci E. , Kabasakal L. , Toklu T., Ocak M., Sahin O. E. , ALAN SELÇUK N., ...Daha Fazla

NUCLEAR MEDICINE COMMUNICATIONS, cilt.39, ss.789-796, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 39 Konu: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1097/mnm.0000000000000874
  • Dergi Adı: NUCLEAR MEDICINE COMMUNICATIONS
  • Sayfa Sayıları: ss.789-796

Özet

Purpose Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-177-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-68-DOTATATE PET/computed tomography scans.